Healthcare
X4 Pharmaceuticals, Inc.(XFOR)
Live Price
Offline$4.00
+3.09% today
1Y Change
+65.29%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $50.00M
- Revenue Growth
- +1273.2%
- EPS Growth
- +66.5%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
X4 Pharmaceuticals, Inc. (XFOR) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $4.00 and up 65.3% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +1273.2%, EPS growth of +66.5%, a dividend yield of 0.0%. What stands out right now is revenue +1273.2%, EPS +66.5%, free cash flow +35.9% with operating margin -247.4% and ROIC -32.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines XFOR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+1273.2% vs +7.6% peer median
Operating Margin
Below sector median
-247.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 6, 2026 with an EPS surprise of +20.0% and a revenue surprise of -22.8%.
The operating story is still moving forward
Revenue is running at +1273.2% and EPS at +66.5%, with operating margin around -247.4%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | +20.0% | -2.1% | -3.4% | -8.4% |
2026 Mar 17, 2026 | +38.9% | -4.3% | -9.7% | +2.4% |
2025 Nov 5, 2025 | +12.7% | -1.3% | +9.0% | +7.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XFOR
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
XFOR Max Drawdown
-41.32%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for XFOR and SPY.
Company Overview
X4 Pharmaceuticals, Inc.
NASDAQ Capital Market
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
- Leadership
- Adam R. Craig
- IPO Date
- Nov 16, 2017
- Employees
- 143
- Street Address
- 61 North Beacon Street
- Mailing
- Boston, MA, 02134
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 857 529 8300
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 1.1
- Price/Sales
- 1.4
- Price/Book
- 2.5
Growth
- Revenue
- +1273.2%
- EPS
- +66.5%
- Free Cash Flow
- +35.9%
Profitability
- Gross Margin
- 82.2%
- Operating Margin
- -247.4%
- Net Margin
- -225.6%
- ROE
- -115.3%
- ROIC
- -32.7%
Balance Sheet
- Debt/Equity
- 0.41
- Current Ratio
- 10.16
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.